The US Food and Drug Administration must set forth a standard by which a drug’s “innovation” is defined in determining whether Hatch/Waxman new product exclusivity blocks approval of a subsequent product, a US federal judge has ruled in a dispute related to buprenorphine depot injection formulations.
The agency’s decision that the monthly formulation of Braeburn Pharmaceuticals Inc.'s Brixadi (buprenorphine extended-release injection) cannot be approved until...





